Long-term Study of IMG-007 for Moderate-to-Severe Atopic Dermatitis
This study is evaluating the long-term safety and effectiveness of a drug called IMG-007 for people with moderate-to-severe atopic dermatitis (eczema). Participants will receive IMG-007 as an injection under the skin. The main goal is to see how safe IMG-007 is over time. This study is for adults aged 18 to 75 who have already completed a previous study (IMG-007-203) and are invited to join. The study plans to enroll about 400 people, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll about 400 participants.
- What's involved
- Participants will receive IMG-007 subcutaneously (under the skin). Safety will be evaluated at Baseline and Week 44.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary safety endpoint is measured at Week 44.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
At a glance
Conditions
Where it's being run
23 sites across 15 statesWho to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Evaluate the safety of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitisBaseline, Week 44
Incidence and severity of TEAEs, including treatment-emergent SAEs, AESIs, and AEs leading to discontinuation